title: Bevacizumab 5 or 7.5 mg/kg in metastatic colorectal cancer can be infused safely over 10 minutes.
abstract: BACKGROUND
  Bevacizumab is a humanized monoclonal antibody that blocks vascular endothelial factor. It demonstrated an efficacy in many cancer types. The standard recommendation of administration is the 90-, 60-, and 30-min infusion sequence for all doses. We evaluated in this study the possibility of reducing infusion time to 10 min for bevacizumab given at 5 or 7.5 mg/kg in metastatic colorectal cancer (MCRC).
  
  
  METHODS
  All patients who received bevacizumab for MCRC were analyzed. Patients were divided into two groups: Group A (bevacizumab was given in the 90-, 60-, and 30-min infusion sequence) and group B (bevacizumab was given over 10 min). Patients' medical records were used to identify any hypersensitivity reactions (HSR) possibly related to bevacizumab.
  
  
  RESULTS
  There were 38 patients in group A and 43 in group B. In group A, 459 doses of bevacizumab were given (286 doses at 5 mg/kg and 173 doses at 7.5 mg/kg). No HSR occurred in this group. In group B, 527 doses of bevacizumab were given (335 doses at 5 mg/kg and 192 doses at 7.5 mg/kg). Only two events of HSR grade 2 were reported in the 7.5 mg/kg infusions. Both of them were easily resolved with symptomatic treatment.
  
  
  CONCLUSIONS
  Bevacizumab 5 or 7.5 mg/kg in MCRC can be infused safely over 10 min.
authors.affiliation: Department of Medical Oncology, Military Hospital Mohammed V, Rabat, Morocco. mahfoudtarik@hotmail.fr
authors.forename: Tarik
authors.initials: T
authors.lastname: Mahfoud
authors.forename: Rachid
authors.initials: R
authors.lastname: Tanz
authors.forename: Mohamed
authors.initials: M
authors.lastname: Mesmoudi
authors.forename: Mohamed Réda
authors.initials: MR
authors.lastname: Khmamouche
authors.forename: Aziz
authors.initials: A
authors.lastname: Bazine
authors.forename: Rachid
authors.initials: R
authors.lastname: Aassab
authors.forename: Nabil
authors.initials: N
authors.lastname: Ismaili
authors.forename: Saber
authors.initials: S
authors.lastname: Boutayeb
authors.forename: Mohamed
authors.initials: M
authors.lastname: Ichou
authors.forename: Hassan
authors.initials: H
authors.lastname: Errihani
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004342:Drug Hypersensitivity / Q000453:epidemiology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012189:Retrospective Studies
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab